Investigational Allergy Immunotherapy Tablet Phase III Results Announced

Merck presented the results from a Phase III clinical study of its investigational allergy immunotherapy tablet (AIT) for ragweed pollen at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Orlando, which demonstrated that in comparison to placebo, AIT substantially lowered the overall combined score that is used to measure nasal and eye symptoms an...

Source: http://www.medicalnewstoday.com/articles/242551.php

Keep You With Me Ice Cream Paint Job Hang It Up Yummy